Sofgen Pharma S.A PROCF

0.00 0.00 NaN as of 24 Sep
Market cap
$114.0M
P/E
0.0×

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '23 Sep '23 Jun '23 Mar '23 Older periods
Revenue
423.75 407.38 399.37 401.74

+8 more TTM periods

Cost of Revenue
185.77 183.91 176.75 167.67
Gross Profit
237.98 223.47 222.62 234.07
SG&A Expenses
193.35 192.37 187.36 195.77
Operating Income
72.08 3.48 7.64 10.68
Interest Expense (Operating)
— 49.42 44.75 39.92
Non-operating Income/Expense
(26.12) 59.30 74.09 23.83
EBT
45.96 62.78 81.73 34.50
Income Tax Provision
5.62 16.99 21.56 8.20
Income after Tax
40.34 45.79 60.18 26.30
Net Income Common
40.34 45.79 60.18 26.30
EPS (Basic)
0.41 0.46 0.60 0.26
Gross Margin
56.16% 54.85% 55.74% 58.26%
EBIT Margin
17.01% 0.85% 1.91% 2.66%
EBT margin
10.85% 15.41% 20.47% 8.59%
Net Profit Margin
9.52% 11.24% 15.07% 6.55%
Free Cash Flow Margin
17.66% 7.85% (2.36%) (5.22%)
EBITDA
90.28 20.94 24.14 27.73
EBIT
72.08 3.48 7.64 10.68
EPS (Diluted, from Cont. Ops)
0.40 0.45 0.60 0.26
EPS (Basic, Consolidated)
0.40 0.45 0.60 0.26
EPS (Basic, from Continuous Ops)
0.40 0.45 0.60 0.26
Income from Continuous Operations
40.34 45.79 60.18 26.30
Consolidated Net Income/Loss
40.34 45.79 60.18 26.30
EBITDA Margin
21.30% 5.14% 6.04% 6.90%
Operating Cash Flow Margin
25.40% 15.82% 5.71% 3.07%

Fold the line items

In millions of $ except per-share values · columns are period end dates